NASDAQ:TWST - Twist Bioscience Stock Price, Forecast & News

Twist Bioscience trades on the NASDAQ under the ticker symbol "TWST."

Twist Bioscience Corp (NASDAQ:TWST) posted its quarterly earnings data on Wednesday, December, 11th. The company reported ($0.96) EPS for the quarter, missing the Zacks' consensus estimate of ($0.84) by $0.12. The business earned $15.74 million during the quarter, compared to analysts' expectations of $14.08 million. Twist Bioscience had a negative net margin of 197.98% and a negative return on equity of 73.98%. View Twist Bioscience's Earnings History.

Twist Bioscience is scheduled to release their next quarterly earnings announcement on Thursday, February 6th 2020. View Earnings Estimates for Twist Bioscience.

Twist Bioscience issued an update on its first quarter 2020 After-Hours earnings guidance on Wednesday, December, 11th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $$15-16.5 million, compared to the consensus revenue estimate of $$15.92 million.

1 brokers have issued 1-year target prices for Twist Bioscience's shares. Their forecasts range from $26.66 to $26.66. On average, they anticipate Twist Bioscience's share price to reach $26.66 in the next year. This suggests a possible upside of 19.8% from the stock's current price. View Analyst Price Targets for Twist Bioscience.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Twist Bioscience in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Twist Bioscience.

News headlines about TWST stock have been trending extremely negative recently, InfoTrie Sentiment reports. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Twist Bioscience earned a media sentiment score of -5.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an impact on the stock's share price in the next few days. View News Stories for Twist Bioscience.

Twist Bioscience saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 4,300,000 shares, an increase of 17.5% from the December 15th total of 3,660,000 shares. Based on an average daily trading volume, of 271,300 shares, the short-interest ratio is currently 15.8 days. Approximately 22.9% of the shares of the company are short sold. View Twist Bioscience's Current Options Chain.

Some companies that are related to Twist Bioscience include Halozyme Therapeutics (HALO), Iovance Biotherapeutics (IOVA), Momenta Pharmaceuticals (MNTA), Acceleron Pharma (XLRN), Audentes Therapeutics (BOLD), Denali Therapeutics (DNLI), Fate Therapeutics (FATE), Regenxbio (RGNX), Alector (ALEC), Cortexyme (CRTX), SpringWorks Therapeutics (SWTX), Editas Medicine (EDIT), Orchard Therapeutics (ORTX), Coherus Biosciences (CHRS) and DBV TECHNOLOGIE/S (DBVT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Twist Bioscience investors own include Amarin (AMRN), Canopy Growth (CGC), Catalyst Pharmaceuticals (CPRX), Corbus Pharmaceuticals (CRBP), ProQR Therapeutics (PRQR), TG Therapeutics (TGTX), Zynerba Pharmaceuticals (ZYNE), AbbVie (ABBV), Aurora Cannabis (ACB) and NovaBay Pharmaceuticals (NBY).

(TWST) raised $75 million in an IPO on Wednesday, October 31st 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and Cowen acted as the underwriters for the IPO and Allen & Company and Baird were co-managers.

Twist Bioscience's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Alpine Global Management LLC (0.08%). Company insiders that own Twist Bioscience stock include Bill Peck, James M Thorburn, Keith Crandell, Mark Daniels, Patrick John Finn, Patrick Weiss and William Banyai. View Institutional Ownership Trends for Twist Bioscience.

TWST stock was purchased by a variety of institutional investors in the last quarter, including Alpine Global Management LLC. View Insider Buying and Selling for Twist Bioscience.

Shares of TWST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TWST stock can currently be purchased for approximately $22.26.

Twist Bioscience has a market capitalization of $740.37 million and generates $54.38 million in revenue each year. The company earns $-107,670,000.00 in net income (profit) each year or ($3.92) on an earnings per share basis. Twist Bioscience employs 289 workers across the globe.View Additional Information About Twist Bioscience.

The official website for Twist Bioscience is http://www.twistbioscience.com/.

Twist Bioscience's mailing address is 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 800-719-0671 or via email at [email protected]